Video

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Related Videos
Dr. Richard “Rick" Winneker
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with brown hair.
Related Content
Illustration of red blood cells.
January 20th 2025

Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis

Alex Biese
Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of a woman's body with the spleen emphasized in red.
December 9th 2024

Pelabresib Plus Jakafi Maintains Efficacy in JAK-Naive Myelofibrosis

Jonah Feldman
Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.
Image of blood test.
December 8th 2024

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Morgan Bayer
Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.